What happened
FDA inspected Pine Pharmaceuticals’ outsourcing facility from November 4–14, 2025, and found evidence of insanitary conditions and CGMP violations in production of drugs intended to be sterile. Operators did not sanitize materials, equipment, hands, or sleeves appropriately when moving from the ISO 7 area into the ISO 5 critical area. FDA also found that routine environmental monitoring did not cover manually handled, high-touch staging trays with a difficult-to-clean design. The letter cites inadequate investigations, deficient aseptic and sterilization process procedures and validation, inadequate personnel qualification, and deficient yield and reject-rate controls. FDA said particulate defects could bypass investigation triggers, while undefined “cosmetic” defects could be returned to batches. Responses were considered unsupported or deficient, including failure to establish root causes for particulates and recurring closure or inspection defects, reliance on reinspection and retrospective risk assessments, and incomplete CAPAs. FDA also found inadequate change control and requalification of visual inspectors, incomplete reject-rate corrections, and undefined, operator-dependent mixing parameters without a detailed validation plan.
Why it matters
From a GMP perspective, failures at the ISO 7-to-ISO 5 transfer boundary may increase contamination risk because operator practices and material disinfection are important controls during aseptic operations. Environmental monitoring that excludes high-touch staging trays may not represent production conditions. Weak investigations, permissive reject calculations, and incomplete CAPA can leave recurring particulate, closure, and inspection failures uncontrolled. Undefined process parameters and gaps in inspector qualification may also reduce assurance that batches consistently meet intended quality and purity.
Key topics: Unsanitized ISO 7-to-ISO 5 transfers during sterile production, Inadequate investigations and controls for particulate and visual inspection defects, Undefined mixing parameters and incomplete process validation